预约演示
更新于：2026-02-27
Itraconazole
伊曲康唑
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 ITCZ、Itraconazole (JP17/USP)、Itraconazole Dispersibie + [29] |
作用方式 抑制剂 |
作用机制 fungal CYP51A1抑制剂(真菌细胞色素P450家族成员51抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 (1988-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C35H38Cl2N8O4 |
InChIKeyVHVPQPYKVGDNFY-WGEGMAFPSA-N |
CAS号84625-61-6 |
关联
570
项与 伊曲康唑 相关的临床试验NCT07261150
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
The purpose of the study is threefold:
1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis.
2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis
3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.
1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis.
2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis
3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.
开始日期2026-05-01 |
申办/合作机构 |
NCT07283497
Itraconazole Therapy In Bronchiectasis With Airway Mold: A Single-Arm Pilot Trial Of Feasibility, Safety, And Impact On Respiratory Symptoms And Airway Microbiome Diversity
The primary objective of this study is to evaluate the feasibility of itraconazole therapy in patients with bronchiectasis and airway mold. Feasibility will be assessed through recruitment success, treatment adherence, tolerability, and participant retention. The study will also explore the impact on respiratory symptoms and airway microbiome diversity.
开始日期2026-03-15 |
申办/合作机构 |
NCT07429331
Evaluation of Drug-Drug Interactions Between CS0159 Tablets and Rifampicin/Itraconazole and the Effect of a High-Fat Meal on the Pharmacokinetic Characteristics of CS0159 Tablets in Healthy Adult Participants
Purpose: This study aims to evaluate the effect of food (high-fat, high-calorie meal) on the pharmacokinetic (PK) profile of CS0159 tablets and to assess the drug-drug interactions (DDI) when CS0159 is co-administered with a strong CYP3A4 inducer (rifampicin) and a strong CYP3A4 inhibitor (itraconazole), respectively.
Design:
Part A (DDI - Induction): Single-center, open-label, fixed-sequence design. Sixteen healthy participants will receive a single dose of CS0159 (4 mg) under fasting conditions on Day 1, rifampicin alone (600 mg, QD) under fasting conditions on Days 2-8, and co-administration of CS0159 with rifampicin under fasting conditions on Day 9.
Part B (Food Effect & DDI - Inhibition): Single-center, open-label, two-phase design. Sixteen healthy participants will first undergo a randomized, two-period, two-sequence crossover food effect study (CS0159 4 mg administered under fasting vs. high-fat meal conditions). All participants will then enter the second phase, receiving itraconazole (200 mg, QD) after a meal for 5 consecutive days, followed by co-administration of CS0159 with itraconazole after a high-fat meal on the 6th day.
Endpoints: The primary endpoints are the pharmacokinetic parameters of CS0159 (C
max, AUC
0-t, AUC
0-∞)and other PK parameters (Tmax，t1/2，λz，AUC_%Extrap，Tlag，CL/F，V/F). Secondary endpoints include safety (adverse events, vital signs, laboratory tests, etc.) .
Design:
Part A (DDI - Induction): Single-center, open-label, fixed-sequence design. Sixteen healthy participants will receive a single dose of CS0159 (4 mg) under fasting conditions on Day 1, rifampicin alone (600 mg, QD) under fasting conditions on Days 2-8, and co-administration of CS0159 with rifampicin under fasting conditions on Day 9.
Part B (Food Effect & DDI - Inhibition): Single-center, open-label, two-phase design. Sixteen healthy participants will first undergo a randomized, two-period, two-sequence crossover food effect study (CS0159 4 mg administered under fasting vs. high-fat meal conditions). All participants will then enter the second phase, receiving itraconazole (200 mg, QD) after a meal for 5 consecutive days, followed by co-administration of CS0159 with itraconazole after a high-fat meal on the 6th day.
Endpoints: The primary endpoints are the pharmacokinetic parameters of CS0159 (C
max, AUC
0-t, AUC
0-∞)and other PK parameters (Tmax，t1/2，λz，AUC_%Extrap，Tlag，CL/F，V/F). Secondary endpoints include safety (adverse events, vital signs, laboratory tests, etc.) .
开始日期2026-03-01 |
申办/合作机构 |
100 项与 伊曲康唑 相关的临床结果
登录后查看更多信息
100 项与 伊曲康唑 相关的转化医学
登录后查看更多信息
100 项与 伊曲康唑 相关的专利（医药）
登录后查看更多信息
11,188
项与 伊曲康唑 相关的文献（医药）2026-12-31·ANNALS OF MEDICINE
The association between different regimens of glucocorticoid and antifungal treatment with the prognosis of allergic bronchopulmonary aspergillosis: a retrospective cohort study
Article
作者: Chen, Lei ; Jiang, Hongni ; Wang, Qin ; Xu, Yiding ; Wang, Minghui ; Wang, Sijiao ; Li, Huayin ; Zhu, Xiaodan ; Zhang, Xiaohua
BACKGROUND:
Optimal management of allergic bronchopulmonary aspergillosis (ABPA) remains debated, particularly regarding glucocorticoid (GC) dosage, duration, antifungal selection, and combination therapy. This study evaluated the impact of different regimens on ABPA prognosis.
METHODS:
A total of 76 ABPA patients at Zhongshan Hospital, Fudan University from March 2009 to June 2018 were enrolled and stratified by one-year relapse status. Demographics, treatment details (GC dosage, GC duration, antifungal type), and outcomes (GC dependence, acute exacerbations, lesion resolution, recurrence) were analyzed. Multivariate logistic regression analysis was utilized.
RESULTS:
No significant difference were observed between the relapse group (n = 20) and non-relapse group (n = 56) in baseline demographics, clinical characteristics, or use of GC duration/dosage or antifungals. The mean follow-up time for the relapse and non-relapse groups were 23.95 vs 24.91 months. The former had higher long-term GC use (>3 months) than the non-relapse group (80% vs. 30.36%, p < 0.001). Long-term GC was an independent risk factor for relapse (OR 6.85, 95%CI 1.51-31.51), GC dependence (OR 5.92, 95%CI 1.29-27.11), and acute exacerbations (OR 9.41, 95%CI 2.76-32.06). Conversely, low-dose GC (<7.5 mg/day) reduced relapse risk (OR 0.06, 95%CI 0.01-0.36), GC dependence (OR 0.07, 95%CI 0.01-0.41), and exacerbations (OR 0.16, 95%CI 0.03-0.91). Voriconazole offered superior initial efficacy vs itraconazole (OR 4.42, 95%CI 1.18-16.52) but poorer long-term lesion resolution (OR 0.24, 95%CI 0.06-0.97). Nevertheless, a higher proportion of non-relapse patients had received combination therapy compared to relapse patients (67.9% vs. 50%, p = 0.322).
CONCLUSION:
Long-term GC increases risks of adverse outcomes in ABPA, while low-dose GC demonstrates protective effects. Voriconazole provides better initial response but inferior long-term lesion resolution compared to itraconazole. More non-relapse patients on combination therapy may related to possible benefit of combination therapy. Prospective studies are warranted to confirm these findings.
2026-04-01·VETERINARY RESEARCH COMMUNICATIONS
Emergence of Fusarium oxysporum infection in farmed Labeo rohita: Isolation, growth requirements, antifungal response, and pathogenic potential
Article
作者: Dekari, Debojit ; Chouhan, Nayan ; Shah, Tarang Kumar ; Mohapatra, Subhransu ; Saha, Himadri
Fusarium oxysporum, was isolated from a naturally infected captive-reared Labeo rohita in Tripura, India. The infected fish exhibited clinical signs of fungal growth with haemorrhage on the ventral body surface and erosion of the caudal fin. Morphological identification of fungal colony, including microscopic observation of 5-day-old culture, revealed the presence of multi-septate macroconidia and one-septate microconidia. Growth requirement study revealed that the fungus grew best at 30 °C and pH 6.0. In vitro studies revealed that the isolate produced extracellular enzymes such as caseinase, lipase, starch hydrolase and DNase, which contributed to its pathogenicity. The partial 18 S gene sequence was assigned NCBI accession number PQ013739.1 and confirmed its identity as F. oxysporum. Pathogenicity test by intraperitoneal injection of fungal spore suspension in healthy L. rohita fingerlings with fungal growth at the site of injection; LD50 value obtained by probit analysis was 4.85 × 107 spores/ml. Antifungal susceptibility testing indicated that none of amphotericin B, ketoconazole, itraconazole, clotrimazole, and nystatin produced zones of inhibition against the fungal isolate. In contrast, the fungus exhibited sensitivity to sodium chloride and copper sulfate, with reduced radial growth at salinity levels exceeding 0.5% and CuSO4 concentrations above 25 ppm. Our findings confirm that the F. oxysporum strain is virulent to L. rohita, and highlights the potential utility of salinity and copper sulfate-based management strategies for control of this fungus in aquaculture.
2026-03-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Primary cutaneous blastomycosis in a Chinese-Canadian girl following an insect bite
Article
作者: Liu, Zehu ; Liu, Sujun ; Xia, Xiujiao
BACKGROUND:
Blastomycosis is a disease caused by the dimorphic fungus Blastomyces species. This infection occurs most frequently among individuals residing in the midwestern, southeastern, and south-central United States, as well as in Canadian provinces bordering the Great Lakes and the St. Lawrence Seaway. Sporadic cases have been reported in China, the diagnosis of imported cases remains a significant challenge.
CASE PRESENTATION:
We report a diagnostically challenging case of primary cutaneous blastomycosis in a Chinese-Canadian girl, presenting as two nodules of different sizes on her left lower leg and left arm. The patient was initially diagnosed with insect bite dermatitis in Canada, which showed poor response to treatment. Direct microscopic examination revealed large spherical yeast cells, some with broad-based budding, initially interpreted as protothecosis or coccidioidomycosis. However, metagenomic next-generation sequencing (mNGS) indicated Blastomyces dermatitidis, which was subsequently confirmed by fungal culture and ITS sequencing. The patient was prescribed oral itraconazole at 50 mg/day and has since returned to Canada to continue treatment.
CONCLUSIONS:
For diagnosing infections caused by highly pathogenic pathogens such as imported blastomycosis, the combination of metagenomic next-generation sequencing (mNGS) and direct microscopic examination represents a valuable diagnostic approach.
347
项与 伊曲康唑 相关的新闻（医药）2026-02-26
Plans to License or Monetize our Migraine and Inhalation Assets Continue
FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, "Our focus in the fourth quarter was to advance steps to complete the proposed merger with Cullgen, a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies for the treatment of pain, cancer and other diseases. We continue to work with Cullgen for approval from the China Securities Regulatory Commission, or CSRC, one of the closing conditions of the Merger. Pulmatrix and Cullgen agreed to waive the "No Solicitation" clause in the Merger Agreement to permit each party to explore transactions that may benefit our respective companies while still seeking approval from the CSRC. In conjunction with the proposed merger, Pulmatrix is currently in a process to license or partner its patent portfolio encompassing our iSPERSE™ technology, as well as three related clinical programs, including our Phase 2 ready acute migraine program.
Proposed Merger with Cullgen
As previously reported, on November 13, 2024, the Company entered into an agreement and plan of merger with Cullgen Inc. ("Cullgen"), as amended by Amendment No. 1 thereto on April 7, 2025 (the "Merger Agreement" and such transaction, the "Merger"). If the proposed Merger is completed, the business of Cullgen will continue as the business of the combined company.
Additional information about the Merger Agreement and proposed Merger was previously disclosed in a registration statement on Form S-4 (File No. 333-284993) initially filed with the Securities and Exchange Commission (the "SEC") on February 14, 2025, as amended on April 17, 2025, and May 7, 2025, and declared effective on May 9, 2025.
On June 16, 2025, the Company held a special meeting in lieu of the 2025 annual meeting of Pulmatrix stockholders, at which the Company's stockholders approved the Merger and related proposals. The closing of the Merger is subject to other customary closing conditions, including Nasdaq's approval of the listing of the shares of Pulmatrix common stock to be issued in connection with the Merger and approval from the CSRC.
On December 17, 2025, the Company and Cullgen mutually agreed to waive the "No Solicitation" clause in the Merger Agreement in order to permit each party to explore alternate transactions while continuing to work toward merger approval from the CSRC.
Pulmatrix Currently Seeking License or Monetization of Clinical Assets and Proprietary iSPERSE™ Technology
iSPERSE™ Technology
iSPERSE™, also licensed to MannKind Corporation and Cipla Technologies for certain fields of use, utilizes particles that are engineered with a small, dense and dispersible profile to exceed the performance of traditional dry powder particles as the iSPERSE™ particles have the dispersibility advantages of porous engineered particles. Pulmatrix believes this results in superior drug delivery compared to traditional oral and injectable forms of treatment for certain diseases.
As of December 31, 2025, Pulmatrix's patent portfolio related to iSPERSE™ included approximately 149 granted patents, 18 of which are U.S.-granted patents, plus approximately 48 pending patent applications in the U.S. and other jurisdictions.
PUR3100
PUR3100, a Phase 2-ready asset, is an orally inhaled dihydroergotamine ("DHE") engineered with Pulmatrix's iSPERSE™ dry powder inhalation technology for the treatment of acute migraine has a Food and Drug Administration acceptance of an Investigational New Drug ("IND") application for PUR3100 and receipt of a "study may proceed" letter to proceed with a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine.
The Phase 2 IND builds on the Phase 1 trial results of PUR3100, which were published in 2024 in the peer-reviewed publication, Headache: The Journal of Head and Face Pain. The study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels. The PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations of nausea and vomiting in the intravenously ("IV") administered DHE dose group.
PUR1800
PUR1800 is a Narrow Spectrum Kinase Inhibitor ("NSKI"), engineered with our iSPERSE™ technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease ("AECOPD"). In 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for AECOPD, indicating PUR1800 was well-tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases.
In 2024, Pulmatrix published an abstract titled "Ex vivo evaluation of the potential for Narrow Spectrum Kinase inhibitors as a treatment for Idiopathic Pulmonary Fibrosis".
PUR1900
PUR1900, approved to proceed to a Phase 3 in India conducted by our partner Cipla, is the Company's inhaled iSPERSE™ formulation of the antifungal drug itraconazole being investigated for various indications. The Company and its partner, Cipla, wound down a Phase 2b trial that the Company was operating in 2024. Cipla has continued clinical development outside the United States, and in 2025 completed their Phase 2 study in India and have been approved by India's Central Drug Standard Control Organization to proceed with a Phase 3 clinical trial.
Pulmatrix will receive 2% royalties on any potential future net sales by Cipla outside the United States should Cipla successfully market PUR1900 outside the United States. Within the United States, the Company and Cipla share the rights 50/50 and will seek to monetize PUR1900 for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need.
Fourth Quarter and Year-End 2025 Financial Results
Revenues decreased to nil for the year ended December 31, 2025, compared to $7.8 million for the year ended December 31, 2024. Revenues recognized for the year ended December 31, 2024, were primarily generated from the Cipla Agreement as related to our PUR1900 program, for which wind down activities were completed during the year ended December 31, 2024.
Research and development expenses decreased approximately $7.1 million to less than $0.1 million for the year ended December 31, 2025, compared to $7.2 million for the year ended December 31, 2024. The decrease was primarily due to the wind down of the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.
General and administrative expenses decreased approximately $2.7 million to $5.1 million for the year ended December 31, 2025, compared to $7.8 million for the year ended December 31, 2024. The decrease was primarily due to decreased employment and other operating costs due to the previously mentioned wind down, partially offset by incurred costs related to the proposed Merger.
The Company's total cash and cash equivalents balance as of December 31, 2025, was $4.1 million, compared to 9.5 million for the year ended December 31, 2024. The Company anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund its operations into the first quarter of 2027.
About Pulmatrix, Inc.
Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes.
About iSPERSE™ Technology
Pulmatrix's innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies. iSPERSE™ is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs. iSPERSE™ can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.
For more on the Company's inhaled product candidates please visit:
.
Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that," "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the consummation of and the exact timing of the proposed Merger with Cullgen, the receipt of applicable regulatory approvals in connection with the proposed Merger with Cullgen, and satisfaction of closing conditions thereunder, among others; the Company's ability to divest its clinical assets on terms favorable to the Company, or at all, the Company's ability to maintain compliance with the listing standards of the Nasdaq Capital Market; the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, including the proposed Merger with Cullgen, is set forth in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Chuck Padala
Managing Director
LifeSci Advisors
646-627-8390
[email protected]
SOURCE Pulmatrix Inc.
21%
more press release views with
Request a Demo
临床1期临床2期临床结果财报并购
2026-02-26
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
疫苗信使RNA临床1期临床研究
2026-02-26
肺癌
1. Acting on dormancy: the interplay between the actin cytoskeleton and tumor cell dormancy.
肌动蛋白细胞骨架与肿瘤细胞休眠的相互作用。休眠的播散性肿瘤细胞是转移复发的根源，其逃避免疫监管的机制尚不明确。研究发现TGF-β驱动的杂合EMT状态通过上调凝胶蛋白使细胞变圆变软，从而躲避免疫清除。抑制该通路可使休眠细胞恢复刚性并被免疫系统识别，为预防癌症复发提供了新靶点。
肿瘤休眠与转移复发 | 凝胶蛋白(Gelsolin), TGF-β, 细胞骨架 | 免疫逃逸模型
Sabol Hayley M · … · Borriello Lucia · · 2026/02/24
该研究由Fox Chase癌症中心Borriello Lucia团队完成 Cancer research
原文链接：https://doi.org/10.1158/0008-5472.CAN-26-0793
2. Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis.
翻译起始因子eIF6通过整合素-FAK轴调节小细胞肺癌可塑性。小细胞肺癌（SCLC）极易产生耐药，其在神经内科与非神经内分泌状态间的转换是导致治疗失败的关键。研究发现eIF6在非神经内分泌状态中显著上调，通过与CD104-FAK复合物互作激活MAPK通路驱动转分化。该研究确定了eIF6是SCLC耐药的重要调节因子，为克服化疗耐药提供了潜在治疗靶点。
小细胞肺癌, 肿瘤可塑性 | eIF6, FAK信号通路 | 翻译组重塑分析
Peng Haoning · … · Shen Shensi · · 2026/02/24
该研究由四川大学华西医院Shen Shensi团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69899-8
3. SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis.
SATB2通过招募HDAC3介导H3K9去乳酸化抑制肺癌生长与转移。SATB2在肺癌中是已知的抑癌因子，但其表观遗传机制尚不明确。研究发现SATB2通过降低H3K9乳酸化水平来抑制癌蛋白LCN2的转录，从而阻断肿瘤进展。该发现揭示了肺癌中新型的表观遗传-代谢交互通路，为治疗提供了潜在靶点。
非小细胞肺癌(NSCLC) | SATB2, H3K9乳酸化, LCN2 | CUT&Tag, RNA-seq
Wen Ting · … · Chen Qiao Yi · · 2026/02/25
该研究由西安交通大学基础医学院Qiao Yi Chen团队完成 Advanced science (Weinheim, Baden-Wurttemberg, Germany)
原文链接：https://doi.org/10.1002/advs.202522996
乳腺癌
1. In Silico Reconstruction of Primary and Metastatic Tumor Architecture using Geographic Information System-Augmented Spatial Transcriptomics.
GIS增强的空间转录组学框架助力肿瘤架构重建。肿瘤微环境的复杂异质性对治疗响应至关重要，但传统分析方法主观性较强。本研究开发了GIS-ROTA框架，整合生物学功能与空间自相关分析，揭示了乳腺癌中雌激素响应与代谢通路的共定位。该工具为识别治疗新靶点提供了具有功能相关性的空间模式分析手段。
肿瘤微环境异质性 | 雌激素响应, 代谢通路 | 空间转录组学, GIS-ROTA
Yoo Jin Young · … · Madak-Erdogan Zeynep · · 2026/02/24
该研究由University of Illinois Urbana-ChampaignMadak-Erdogan Zeynep团队完成 Cancer research
原文链接：https://doi.org/10.1158/0008-5472.CAN-25-3161
2. Context-dependent translation inhibition as a cancer therapeutic modality.
翻译抑制剂精准打击三阴性乳腺癌。针对人类核糖体肽酰转移酶中心的上下文依赖性抑制剂开发仍是空白。研究通过结构设计合成出能特异性结合特定氨基酸序列的抑制剂，并在小鼠模型中证实了其抗肿瘤活性。该研究为治疗难治性癌症提供了一种靶向致癌依赖因子的全新小分子疗法。
三阴性乳腺癌 | 核糖体肽酰转移酶中心, 翻译延伸 | 结构导向药物设计
Diamond Paige D · … · Schuller Anthony P · · 2026/02/24
该研究由Interdict Bio Inc.的Anthony P. Schuller团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69891-2
血液肿瘤
1. Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor.
联合BET蛋白与BRG1/BRM抑制剂克服AML对Menin抑制剂的耐药性。Menin抑制剂在治疗特定AML中效果显著但易产生耐药。研究通过CRISPR筛选发现BRD4和SMARCA4是关键耐药靶点，联合使用相关抑制剂可协同诱导耐药细胞死亡。该联合用药方案在异种移植模型中显著延长了生存期，为克服临床耐药提供了新策略。
急性髓系白血病(AML), 药物耐药 | Menin抑制剂, BRD4, SMARCA4 | CRISPR筛选, 异种移植模型
Fiskus Warren · … · Bhalla Kapil N · · 2026/02/24
该研究由MD安德森癌症中心Bhalla Kapil N团队完成 Blood
原文链接：https://doi.org/10.1182/blood.2025031486
2. A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.
伊曲康唑可作为急性髓系白血病氧化磷酸化抑制剂。AML治疗中线粒体代谢靶向药物匮乏，亟需安全有效的临床药物。研究通过高通量筛选发现伊曲康唑通过抑制CYP51A1干扰电子传递链复合体I，从而阻断OXPHOS。该发现为清除耐药白血病干细胞提供了临床可行的老药新用方案。
急性髓系白血病 (AML) | 氧化磷酸化 (OXPHOS), CYP51A1, 电子传递链 | 药物筛选, 老药新用
Himonas Ekaterini · … · Helgason Vignir · · 2026/02/24
该研究由University of GlasgowHelgason Vignir团队完成 Blood
原文链接：https://doi.org/10.1182/blood.2024027853
3. Acrylamide Bioisosterism: Alkenyl Aromatic Heterocycles as Reactivity-Tunable Warheads for Covalent BTK Inhibitors.
烯基芳香杂环作为新型弹头提升共价BTK抑制剂性能。传统共价抑制剂的丙烯酰胺弹头在生理条件下存在稳定性和选择性不足的挑战。研究通过生物电子等排原理开发了反应性可调的烯基杂环弹头，并成功应用于伊布替尼改造，实现了强效且选择性的BTK抑制。该策略为共价药物开发提供了创新的化学工具，具有广泛的抗肿瘤药物研发潜力。
B细胞肿瘤 | BTK, 共价抑制剂 | 生物电子等排, 药物化学
Li Yang · … · Ouyang Liang · · 2026/02/24
该研究由四川大学华西医院Ouyang Liang团队完成 Journal of medicinal chemistry
原文链接：https://doi.org/10.1021/acs.jmedchem.5c03212
4. Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients.
冷冻电镜揭示多发性骨髓瘤患者抗体轻链纤维结构。多发性骨髓瘤常伴随淀粉样变性，但患者体内原位形成的轻链纤维结构尚不明确。研究从患者脂肪活检中提取并解析了三种独特的轻链纤维结构，发现其与系统性淀粉样变性存在显著差异。这些发现为多发性骨髓瘤的分子诊断和发病机制研究提供了重要的结构依据。
多发性骨髓瘤(MM) | 抗体轻链, 淀粉样纤维 | 冷冻电镜, 脂肪活检
Yao Yuxuan · … · Li Dan · · 2026/02/24
该研究由上海交通大学李丹团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69784-4
5. Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.
揭示儿童B细胞急性淋巴细胞白血病CAR-T治疗失败因素。尽管CAR-T疗法显著改善了B-ALL预后，但仍有30-50%的患者面临早期失败或复发。研究分析发现CD19抗原丢失、高肿瘤负荷及既往药物暴露是导致预后不良的关键因素。该研究强调了CAR-T治疗失败后的严峻预后，并指出了开发新型挽救策略的紧迫性。
B细胞急性淋巴细胞白血病 | CD19抗原丢失, CAR-T耐药 | 临床回顾性分析
Lecornec Nicolas · … · Boissel Nicolas · · 2026/02/24
该研究由圣路易斯大学医院Nicolas Boissel团队完成 Leukemia
原文链接：https://doi.org/10.1038/s41375-026-02867-9
6. Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.
构建TP53突变骨髓增殖性肿瘤风险分层模型。TP53突变虽增加白血病转化风险，但并非所有携带该突变的MPN患者预后均一致。研究通过分析1540名患者数据，确定了骨髓纤维化和多位点突变为独立预后因素，并建立了三级风险评分系统。该评分系统有助于精准识别高危患者，为慢性期MPN的临床决策提供指导。
骨髓增殖性肿瘤 | TP53突变, 骨髓纤维化 | 风险分层模型
Rolles Benjamin · … · Mullally Ann · · 2026/02/24
该研究由斯坦福大学Ann Mullally团队完成 Leukemia
原文链接：https://doi.org/10.1038/s41375-026-02885-7
消化肿瘤
1. Ribonuclease 5/Angiogenin Suppresses Intestinal Tumor Initiation by Maintaining Crypt Homeostasis.
核糖核酸酶5通过维持隐窝稳态抑制肠道肿瘤起始。RNase5通常被认为促进肿瘤进展，但其在早期成瘤中的作用尚不明确。研究发现RNase5通过产生tiRNAs限制蛋白质合成，从而抑制隐窝干细胞的过度增殖。血清RNase5水平与结直肠癌风险呈负相关，为大肠癌的早期预防提供了新的干预选择。
结直肠癌预防 | RNase5, tiRNAs, 隐窝稳态 | 嵌套病例对照研究, 肠道类器官
Shi Xiaoliang · … · Xu Zhengping · · 2026/02/24
该研究由浙江大学许正平团队完成 Cancer research
原文链接：https://doi.org/10.1158/0008-5472.CAN-25-1827
2. Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer.
浆素蛋白驱动胃癌中LAG3+调节性T细胞的分化与免疫抑制。Treg细胞的富集是胃癌免疫逃逸的关键，但其分化驱动机制尚不清楚。研究通过单细胞测序发现肿瘤源性浆素蛋白通过CD44信号通路促进LAG3+ Treg分化。阻断该轴可解除免疫抑制并抑制肿瘤进展，为提高胃癌免疫治疗疗效提供了新靶点。
胃癌免疫抑制 | 浆素蛋白(Serglycin), LAG3, CD44 | 单细胞RNA测序, 免疫治疗
Wang Qingyuan · … · Shen Lizong · · 2026/02/24
该研究由南京医科大学沈历宗团队完成 Cancer research
原文链接：https://doi.org/10.1158/0008-5472.CAN-25-3071
3. Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer.
放疗联合TIM-3/PD-L1阻断增强结直肠癌免疫疗效。大多数结直肠癌对免疫检查点抑制剂反应不佳，放疗虽能促进免疫但也会诱导适应性免疫抑制。研究通过多组学分析及小鼠模型发现，放疗诱导TIM-3和PD-1共表达，三联疗法在MSS型肿瘤中表现出最强的抗肿瘤活性。该研究确定了放疗后的适应性耐药轴，为难治性结直肠癌的临床联合治疗提供了理论依据。
结直肠癌, 免疫耐药 | TIM-3, PD-L1, 放疗 | 联合免疫治疗
Wang Xuan Xuan · … · Sun Xiaonan · · 2026/02/24
该研究由浙江大学医学院附属邵逸夫医院Sun Xiaonan团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-013656
4. Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition.
异体NK细胞疗法通过规避HLA I抑制有效治疗胰腺癌。胰腺导管腺癌进展快且免疫治疗效果差，亟需探索基于自然杀伤（NK）细胞的新型免疫策略。研究发现胰腺癌进展中激活配体丢失，而通过选择规避KIR-HLA抑制的异体NK细胞能显著增强对肿瘤的控制能力。该研究强调了供体选择在NK细胞疗法中的关键作用，为胰腺癌的异体细胞治疗提供了优化方向。
胰腺癌 | NK细胞, KIR-HLA相互作用 | 过继性细胞疗法
Lee Stacey N · … · Boudreau Jeanette E · · 2026/02/24
该研究由达尔豪斯大学Boudreau Jeanette E团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-013796
5. Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".
PSCA靶向的Vδ1 γδ T细胞为胰腺癌免疫治疗带来新希望。传统γδ T细胞疗法临床获益有限，工程化CAR技术有望提升其肿瘤特异性与持久性。本文评述了Vδ1亚群在组织驻留和抗耗竭方面的优势，并对比了不同T细胞亚群在PSCA靶向治疗中的转录特征。该研究强调了针对特定γδ T细胞亚群进行优化的必要性，为实体瘤细胞疗法的发展指明了方向。
胰腺癌 | PSCA, γδ T细胞, CAR-T | 过继性免疫治疗
de Bont Dorine A · … · Kuball Jurgen · · 2026/02/24
该研究由乌得勒支大学医学中心Jurgen Kuball团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-014199
6. HOXD13-mediated immune crosstalk between cancer cells and tumor-associated macrophages drives colorectal cancer progression.
HOXD13介导的癌细胞与巨噬细胞互作驱动结直肠癌进展。结直肠癌微环境的免疫抑制机制复杂，寻找诱导该环境的肿瘤内源性因子至关重要。研究发现HOXD13通过上调AREG和PILRA促进M2型巨噬细胞极化，形成互作反馈环路抑制CD8+ T细胞功能。该研究揭示了HOXD13在免疫逃逸中的关键作用，为结直肠癌的增敏治疗提供了新靶点。
结直肠癌, 肿瘤微环境 | HOXD13, M2型巨噬细胞, AREG | 基因敲除小鼠模型
Chen Xilang · … · Xia Limin · · 2026/02/24
该研究由华中科技大学同济医学院附属同济医院Xia Limin团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-014028
7. Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.
联合抑制PARP与KRASG12D可增强胰腺癌疗效。KRASG12D突变驱动的胰腺癌对单药治疗易产生耐药，亟需寻找更有效的联合治疗方案。研究发现阻断KRASG12D会下调同源重组修复相关蛋白，诱导修复缺陷并使肿瘤细胞对PARP抑制剂产生合成致死效应。该策略在体内外模型中均表现出显著的协同抗肿瘤活性及免疫激活效果。
胰腺癌(PDAC) | KRASG12D, PARP抑制剂, 合成致死 | 联合用药, 肿瘤免疫微环境重塑
Xu Xin · … · Deng Min · · 2026/02/24
该研究由中国医学科学院肿瘤医院邓敏团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69695-4
8. Discovery of a Novel Dual-Targeting KRASG12D/HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer.
新型KRASG12D/HDAC双靶向肽抑制剂用于胰腺癌治疗。胰腺癌恶性程度高且治疗手段有限，KRAS与HDAC在其进展中起关键作用。研究通过虚拟筛选鉴定出肽抑制剂KH-1，能同时高亲和力结合两个靶点并诱导细胞凋亡。KH-1在体内外均展现出显著的抑瘤效果，是极具前景的胰腺癌治疗候选药物。
胰腺癌 | KRASG12D, HDAC2, 双靶向抑制 | 肽抑制剂, 虚拟筛选, 微量热泳动(MST)
Zhang Qiaoxuan · … · Hu Weiwei · · 2026/02/25
该研究由中国药科大学Weiwei Hu团队完成 Journal of medicinal chemistry
原文链接：https://doi.org/10.1021/acs.jmedchem.5c02435
妇科肿瘤
1. Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance.
肿瘤源性干扰素重塑巨噬细胞生态位导致PARP抑制剂耐药。PARP抑制剂在卵巢癌治疗中面临耐药挑战，其背后的空间免疫微环境演变机制不明。研究通过空间蛋白组学发现，持续的IFN信号诱导巨噬细胞表达骨桥蛋白（SPP1），形成免疫抑制微环境。阻断SPP1可逆转耐药并增强T细胞杀伤，为克服PARPi耐药提供了空间靶向新策略。
卵巢癌, PARP抑制剂耐药 | SPP1, 干扰素信号, 肿瘤相关巨噬细胞 | 空间蛋白组学, 单细胞测序
Liu Dan · … · Gao Qinglei · · 2026/02/26
该研究由华中科技大学同济医院高庆蕾团队完成 The Journal of clinical investigation
原文链接：https://doi.org/10.1172/JCI199035
2. Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.
靶向嘧啶合成可克服卵巢癌对PARP抑制剂的耐药性。PARP抑制剂耐药是卵巢癌治疗中的重大挑战，亟需寻找新的增敏策略。研究发现铜离子载体elesclomol能通过干扰ATR-ATRIP相互作用抑制DNA修复，并揭示了耐药细胞对嘧啶合成的代谢依赖。该研究为克服卵巢癌耐药提供了联合靶向代谢与DNA修复的新策略。
卵巢癌耐药 | ATR通路, 嘧啶合成, 铜离子载体 | 小分子筛选, 代谢脆弱性分析
Nan Yabing · … · Liu Zhihua · · 2026/02/25
该研究由中国医学科学院肿瘤医院刘芝华团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-70001-5
神经肿瘤
1. The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A.
N-Myc与Aurora A激酶的动态互作机制被成功揭示。MYC蛋白的内在无序特性使其与伴侣蛋白的互作难以表征，阻碍了针对性抗癌药物的开发。研究利用整合结构生物学方法发现N-Myc通过多个保守基序与Aurora A结合并变构激活激酶，且该作用可被小分子抑制。该研究为开发破坏N-Myc复合物的治疗策略提供了结构基础，对神经内分泌肿瘤治疗具有重要意义。
神经内分泌肿瘤 | N-Myc, Aurora A, 变构激活 | 整合结构生物学
Hultman Johanna · … · Sunnerhagen Maria · · 2026/02/24
该研究由林雪平大学Maria Sunnerhagen团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69725-1
2. NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation.
NIBAN2/FLII/RREB1轴通过激活TLR3通路驱动胶质瘤干细胞恶性进展。胶质瘤干细胞是肿瘤侵袭和复发的根源。研究发现NIBAN2通过增强FLII与RREB1交互激活TLR3信号，维持干细胞特性并促进糖酵解代谢。联合使用奈非那韦与LDHA抑制剂可产生协同抗肿瘤效果，为胶质瘤精准治疗提供了新靶点。
胶质瘤干细胞, 肿瘤复发 | NIBAN2, TLR3通路, 糖酵解 | 代谢组学, PDX模型, 联合用药
Shi Liang Liang · … · Li Junjun · · 2026/02/25
该研究由华中科技大学同济医学院附属协和医院Junjun Li团队完成 Advanced science (Weinheim, Baden-Wurttemberg, Germany)
原文链接：https://doi.org/10.1002/advs.202519382
罕见癌种
1. Ameloblastoma Displays Primary Cilia Maintenance and CEP164 Overexpression.
成釉细胞瘤通过CEP164维持初级纤毛促进肿瘤发生。成釉细胞瘤具有局部侵袭性，但其初级纤毛的维持状态及其在致病中的作用仍不明确。研究发现该肿瘤独特地保留了初级纤毛，且CEP164的过表达是介导纤毛形成及Hh通路激活的关键。该研究为成釉细胞瘤的生物学机制提供了新见解，并识别了潜在的诊断与治疗靶点。
成釉细胞瘤 | 初级纤毛, CEP164, Hh通路 | 免疫组化, 转录组筛选
Miyazaki R · … · Shinmura K · · 2026/02/24
该研究由滨松医科大学Shinmura K团队完成 Journal of dental research
原文链接：https://doi.org/10.1177/00220345261417597
2. Ultrasound - Responsive bone - Targeting liposomes suppress osteosarcoma through enhanced ROS generation and immunogenic cell death.
超声响应骨靶向脂质体显著抑制骨肉瘤生长。骨肉瘤深部浸润及缺氧微环境限制了传统疗法的疗效，亟需高效的声动力治疗策略。研究开发了负载MnO2和ICG的骨靶向纳米脂质体，通过缓解缺氧、增强ROS产生并激活cGAS-STING通路诱导免疫原性细胞死亡。该纳米免疫放大器策略为骨肉瘤的声动力联合免疫治疗提供了新思路。
骨肉瘤 | ROS产生, cGAS-STING通路 | 声动力治疗, 纳米脂质体
Xu Jingtao · … · Ou Yunsheng · · 2026/02/22
该研究由重庆医科大学附属第一医院Ou Yunsheng团队完成 Journal of controlled release : official journal of the Controlled Release Society
原文链接：https://doi.org/10.1016/j.jconrel.2026.114746
3. SFPQ directs histone H3.3 deposition to R-loops in DNA repeats to protect genome stability.
SFPQ通过引导H3.3沉积至R-loop区域维护基因组稳定性。重复DNA序列易形成R-loop，若处理不当会引发复制压力和DNA损伤，导致基因组不稳定。研究发现SFPQ招募伴侣蛋白DAXX促进H3.3掺入，抑制R-loop积累并防止cGAS/STING通路介导的先天免疫激活。该发现阐明了保护基因组的新机制，并提示其与肉瘤患者的生存预后密切相关。
基因组稳定性, 肉瘤 | SFPQ, R-loop, H3.3 | 染色质免疫沉淀
Ferrando Alessandro · … · Schoeftner Stefan · · 2026/02/24
该研究由的里雅斯特大学Stefan Schoeftner团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69479-w
泛癌种
1. A versatile self-adjuvanting macro-microporous ZIF-8@Mn MOF platform for efficient antigen capture and presentation to boost antitumor immunity
新型MOF平台增强原位肿瘤疫苗免疫疗效。个性化原位肿瘤疫苗受限于抗原交叉呈递不足及免疫抑制微环境。研究构建了集成PROTAC降解剂与锰基MOF的平台，通过诱导免疫原性细胞死亡并高效捕获抗原，激活STING通路促进T细胞免疫。该平台显著抑制肿瘤生长，为提升肿瘤免疫治疗效率提供了高效方案。
肿瘤免疫治疗 | 免疫原性细胞死亡, STING通路, 抗原呈递 | 金属有机框架, PROTAC
Zuo, Qinhua · … · Xue, Wei · · 2026/02/26
该研究由暨南大学薛巍团队完成 Journal of Controlled Release
原文链接：https://www.sciencedirect.com/science/article/pii/S0168365926001094?dgcid=rss_sd_all
2. Aptamer-Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer.
适配体脂质体平台助力前列腺癌免疫治疗。前列腺癌作为“冷肿瘤”，因cDC1数量减少和免疫抑制环境导致免疫治疗效果不佳。研究开发了Apt-Flt3L@Lipo平台，通过超声触发诱导肿瘤细胞死亡并促进cDC1募集与活化。该原位疫苗策略显著增强了T细胞免疫，为治疗免疫冷肿瘤提供了新思路。
前列腺癌 | cDC1, Flt3L, 免疫原性细胞死亡 | 适配体修饰脂质体, 原位疫苗
Wang Jiayi · … · Yang Yu · · 2026/02/24
该研究由上海交通大学仁济医院杨斌团队完成 Advanced science (Weinheim, Baden-Wurttemberg, Germany)
原文链接：https://doi.org/10.1002/advs.202522169
3. Harnessing Unique Boron Chemistry to Develop a New Class of Non-hydroxamate HDAC Inhibitors with Validated In Vivo Efficacy.
硼酸类新型HDAC抑制剂展现强效抗肿瘤活性。硼元素的动态共价反应性在金属酶药效团设计中具有潜力，但尚未得到充分开发。研究设计并优化了硼酸基HDAC抑制剂Z16，其在多种细胞系及异种移植模型中表现出优异的药效。该研究确立了Z16作为非羟肟酸类抑制剂的领先地位，突显了硼酸在药物研发中的价值。
肿瘤治疗 | HDAC抑制剂, 硼酸药效团 | 药物设计与合成
Zhou Li-Yan · … · Chen Fen-Er · · 2026/02/24
该研究由复旦大学/四川大学陈芬儿团队完成 Journal of medicinal chemistry
原文链接：https://doi.org/10.1021/acs.jmedchem.5c03600
4. 68Ga/161Tb-Labeled CXCR4-Targeted Probe with Enhanced Positive Charge: Improved Affinity and Longer Tumor Retention without Survival Benefit in Mice Models.
新型CXCR4靶向探针面临脱靶毒性挑战。优化放射性配体疗法的亲和力是提升疗效的关键，但需平衡正常器官的摄取。研究开发了高亲和力的161Tb-Pentikra探针，虽能抑制肿瘤但因严重的骨髓和消化道毒性未能延长生存。该研究强调了在放射性药物转化中，必须严格平衡配体亲和力与非靶向器官毒性。
肿瘤放射治疗 | CXCR4, 脱靶毒性 | 放射性配体疗法
Yu Xuebing · … · Kang Fei · · 2026/02/24
该研究由空军军医大学西京医院康飞团队完成 Journal of medicinal chemistry
原文链接：https://doi.org/10.1021/acs.jmedchem.5c03763
5. Synthetic gene circuits that selectively target RAS-driven cancers.
合成基因线路实现RAS驱动癌症的精准打击。靶向突变RAS的传统疗法易产生耐药性，且对健康细胞具有潜在毒性。研究设计了集成多个RAS传感器的合成基因线路，能以前所未有的选择性在癌细胞中表达治疗蛋白。该工作展示了合成生物学在肿瘤精准治疗中的潜力，为RAS驱动的癌症提供了新策略。
RAS驱动癌症 | RAS传感器, 基因线路 | 合成生物学
Senn Gabriel Valentin · … · Benenson Yaakov · eLife · 2026/02/24
原文链接：https://doi.org/10.7554/eLife.104320
6. Human oncogenic herpesvirus latency proteins activate NEK2 to promote chromosomal instability and tumorigenesis.
致癌疱疹病毒通过激活NEK2促进染色体不稳定。NEK2激酶在多种癌症中高表达且预后较差，但其受病毒调控的机制不明。研究发现EBV和KSHV的潜伏蛋白通过RBP-Jκ上调NEK2，导致非整倍体增加和细胞增殖。该发现确定了NEK2是病毒诱导肿瘤发生的关键驱动因素及潜在治疗靶点。
疱疹病毒致癌, 染色体不稳定 | NEK2, EBNA2, LANA | 病毒感染模型, 启动子活性分析
Bose Dipayan · … · Robertson Erle S · · 2026/02/24
该研究由宾夕法尼亚大学Robertson Erle S团队完成 Proceedings of the National Academy of Sciences of the United States of America
原文链接：https://doi.org/10.1073/pnas.2535073123
7. Stress-Induced ADGRL4 Orchestrates Tumor Progression and Metastasis by Inhibiting YAP1 Signaling and Activating Angiogenesis.
应激诱导的ADGRL4通过抑制YAP1信号调节肿瘤进展与转移。肿瘤如何适应环境应激并维持生长是癌症研究的核心问题。研究发现ADGRL4作为应激传感器，通过cAMP-PKA通路抑制YAP1活性，从而限制肿瘤扩张。然而，ADGRL4缺失会导致YAP1过度激活并重编程基质信号，该发现揭示了治疗诱导肿瘤进展的新机制。
肿瘤应激适应与转移 | ADGRL4, YAP1, cAMP-PKA信号 | 基因敲除模型, 血管生成分析
Wu Yalan · … · Tang Xiaolong · · 2026/02/24
该研究由湖南大学唐晓龙团队完成 Cancer research
原文链接：https://doi.org/10.1158/0008-5472.CAN-25-4574
8. The path forward for T cell engagers in patients with prostate cancer.
T细胞衔接器在摄护腺癌治疗中展现广阔前景。转移性去势抵抗性前列腺癌治疗手段有限，T细胞衔接器（TCEs）作为新兴免疫疗法备受关注。本文综述了CD3和CD28靶向TCEs的作用机制及临床进展，并提出了结合生物标志物与联合用药的发展路径。该综述为优化前列腺癌免疫治疗策略、提升患者临床获益提供了重要指导。
前列腺癌 | T细胞衔接器(TCEs), CD3, CD28 | 免疫治疗
Subudhi Sumit K · … · Drake Charles G · · 2026/02/24
该研究由强生创新医学中心Charles G Drake团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-013905
9. Macrophage Mtdh deficiency discordantly regulated tumor growth and metastasis through increased thrombospondin-1 production.
巨噬细胞Mtdh缺失差异化调节肿瘤生长与转移。Metadherin (MTDH) 在肿瘤进展中作用显著，但其在巨噬细胞中的具体生物学功能尚不明确。研究发现巨噬细胞Mtdh缺失通过增加TSP-1分泌抑制血管生成从而减少转移，但同时激活TGF-β1促进纤维化进而加速原位生长。该研究揭示了肿瘤生长与转移不一致性的新机制，为靶向MTDH的癌症治疗提供了新视角。
肿瘤转移, 肿瘤生长 | MTDH, TSP-1, TGF-β1 | 髓系特异性敲除小鼠
Jiang Yu · … · Liu Xiuxiu · · 2026/02/24
该研究由山东第一医科大学附属中心医院Liu Xiuxiu团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-013655
10. Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment.
工程化巨噬细胞实现安全有效的CD47肿瘤靶向治疗。肿瘤相关巨噬细胞在微环境中具有双重作用，如何利用其吞噬能力并规避CD47介导的抑制是研究重点。研究开发了受Arg1启动子驱动的CAR-Mφ，能在肿瘤微环境中特异性激活并克服SIRPα抑制，同时降低红细胞毒性。该研究为实体瘤的髓系细胞疗法设计提供了兼顾有效性与安全性的新范式。
实体瘤 | CD47, SIRPα, CAR-M | 巨噬细胞工程化
Andón Fernando Torres · … · Takimoto Chris H · · 2026/02/24
该研究由START中心Takimoto Chris H团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-014457
11. Serotonin transporter SERT: a novel immune checkpoint for CD8+ T cell antitumor therapy.
血清素转运体SERT被鉴定为CD8+ T细胞抗肿瘤治疗的新靶点。肿瘤微环境中的代谢物如何调节免疫反应是当前癌症免疫治疗的研究热点。研究发现SERT通过耗竭肿瘤内5-HT抑制T细胞功能，而SSRI类抗抑郁药能显著增强抗肿瘤免疫并与PD-1阻断协同。该发现确立了SERT的免疫检查点功能，并为老药新用开发癌症免疫疗法提供了重要依据。
肿瘤免疫逃逸 | SERT, 血清素(5-HT), CD8+ T细胞 | SSRIs类药物
Xiao Qing · … · Liu Yao · · 2026/02/24
该研究由重庆大学附属肿瘤医院Liu Yao团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-013294
12. Specific depletion of TIGIThigh CD226- clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting.
特异性清除TIGIThigh CD226-调节性T细胞可提升抗肿瘤疗效。TIGIT阻断剂在临床试验中效果不佳，亟需阐明限制其疗效的关键细胞亚群及机制。研究通过多组学分析发现克隆扩增的TIGIThigh Tregs是主要障碍，利用ADCC增强型抗体清除该亚群可激活Th1反应。该研究为优化TIGIT靶向免疫治疗提供了精准的策略方向和生物标志物参考。
肿瘤免疫抑制 | TIGIT, CD226, Tregs | 单细胞测序, ADCC增强抗体
Zhou Haoyue · … · Zhang Yan · · 2026/02/24
该研究由上海交通大学医学院Zhang Yan团队完成 Journal for immunotherapy of cancer
原文链接：https://doi.org/10.1136/jitc-2025-013636
13. Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.
阻断tRNA苏氨酸化修饰可激发抗肿瘤免疫反应。肿瘤免疫逃逸限制了黑色素瘤的治疗效果，而mRNA翻译在其中的调控机制尚不明确。研究发现OSGEP介导的t6A修饰缺失会导致蛋白质聚集并激活RIG-I通路，从而招募T细胞进入肿瘤。该发现将t6A修饰确定为黑色素瘤免疫治疗的潜在新靶点。
黑色素瘤 | tRNA修饰(t6A), RIG-I通路 | 翻译组学分析, 免疫疗法
Dziagwa Cléa · … · Close Pierre · · 2026/02/25
该研究由列日大学Pierre Close团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69964-2
14. B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities.
新型双特异性抗体IBI334实现肿瘤选择性EGFR抑制。传统EGFR靶向药物因脱靶毒性受限，亟需提高肿瘤选择性以降低副作用。研究开发了结合B7-H3与EGFR的双抗IBI334，通过顺式抑制机制在保证疗效的同时显著降低了系统毒性。该药物已进入临床试验，为治疗多种EGFR阳性实体瘤提供了安全高效的新方案。
实体瘤治疗 | EGFR, B7-H3, 顺式抑制 | 双特异性抗体, 临床前评价
Guan Jian · … · He Kaijie · · 2026/02/24
该研究由信达生物国庆研究院He Kaijie团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-69703-7
15. Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS.
杂化降解共聚物实现MYC与KRAS靶向降解。针对缺乏配体结合口袋的“不可成药”蛋白质，现有的靶向蛋白降解技术仍面临优化难题。研究开发了HYDRAC聚合物平台，通过整合靶向肽与降解子，在体内外成功实现了MYC和KRAS的有效降解。该范式显著扩展了靶向蛋白降解的工具箱，为难治性癌症治疗提供了新策略。
不可成药靶点 | MYC, KRAS, 靶向蛋白降解 | 杂化降解共聚物
Wang Max M · … · Gianneschi Nathan C · · 2026/02/24
该研究由西北大学Nathan C. Gianneschi团队完成 Nature communications
原文链接：https://doi.org/10.1038/s41467-026-68913-3
16. The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations.
GENEVA平台模拟肿瘤嵌合体揭示KRAS抑制剂反应差异。临床药物筛选受限于体内模型规模，难以覆盖患者遗传多样性。本研究开发了单细胞分辨率的GENEVA平台，发现线粒体激活驱动细胞死亡而EMT介导耐药。该平台能有效识别治疗靶点并优化联合用药，缩小临床前模型与疗效间的差距。
肿瘤遗传多样性, 药物耐药性 | KRAS-G12C, 线粒体激活, 上皮-间质转化(EMT) | GENEVA平台, 单细胞测序
Yu Johnny X · … · Goodarzi Hani · Nature cancer · 2026/02/24
⭐ 该研究由University of California, San Francisco (UCSF) Hani Goodarzi团队完成
原文链接：https://doi.org/10.1038/s43018-026-01130-5
17. Engineered TCR-T Cells Secreting IFNα/Anti-PD-L1 Potentiate Endogenous Immunity to Synergistically Bolster the Efficacy Against Solid Tumors.
分泌IFNα/Anti-PD-L1的工程化TCR-T细胞增强实体瘤疗效。TCR-T疗法在实体瘤中因微环境抑制而疗效受限。研究构建了双靶向工程化TCR-T细胞，局部释放IFNα并阻断PD-L1，从而改善微环境并激活内源性NK和DC细胞。该协同策略在确保安全性的同时有效根除实体瘤，具有显著的临床转化潜力。
实体瘤 | TCR-T细胞, IFNα, PD-L1阻断 | 细胞工程化, 联合免疫治疗
Sun Yuan · … · Bai Yun · · 2026/02/24
该研究由北京大学基础医学院Yun Bai团队完成 Molecular therapy : the journal of the American Society of Gene Therapy
原文链接：https://doi.org/10.1016/j.ymthe.2026.02.035
18. Discovery of a Novel Phenyl Thiophene-3-carboxamide Derivative DZX19 as an Orally TRK Inhibitor with Potent Antitumor Effects.
新型口服TRK抑制剂DZX19展现强效抗肿瘤活性。现有TRK抑制剂常因激酶突变产生耐药性。研究通过骨架迁越和结构设计发现DZX19，其对多种耐药突变体具有更强的体外活性，并能诱导细胞凋亡及信号抑制。在异种移植模型中，DZX19显著抑制肿瘤生长，是极具潜力的TRK靶向候选药物。
NTRK融合阳性肿瘤 | TRK抑制剂, 激酶突变耐药 | 药物分子设计, 异种移植模型
Xu Shaoshan · … · Dong Jinhua · · 2026/02/24
该研究由沈阳药科大学Jinhua Dong团队完成 Journal of medicinal chemistry
原文链接：https://doi.org/10.1021/acs.jmedchem.5c01974
19. Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.
人工智能与大语言模型在癌症免疫治疗中的应用综述。预测免疫治疗反应和理解耐药机制是当前肿瘤学的重大挑战。本文系统总结了AI/ML在患者分层、生物标志物发现及策略优化方面的进展，并探讨了基础模型与LLM的潜力。该综述为加速AI集成到精准免疫治疗中提供了行动指南和未来方向。
癌症免疫治疗 | 治疗反应预测, 耐药机制 | 人工智能(AI), 大语言模型(LLM)
Wu Xinchao · … · Wan Shibiao · · 2026/02/25
该研究由University of Nebraska Medical Center Shibiao Wan团队完成 Advanced science (Weinheim, Baden-Wurttemberg, Germany)
原文链接：https://doi.org/10.1002/advs.202521936
20. Multi-Scale Mapping of Gene Expression from Whole-slide Images for Identifying Phenotype-Associated Subpopulations.
BiSCALE框架通过病理图像多尺度映射识别表型相关亚群。发现与表型相关的细胞亚群对精准治疗至关重要。研究开发了BiSCALE深度学习框架，能从常规病理切片中预测组织及细胞水平的基因表达。该方法实现了低成本的多尺度基因分析和风险分层，为临床生物标志物发现提供了强有力工具。
肿瘤异质性, 风险分层 | 基因表达预测, 组织表型 | 深度学习(BiSCALE), 全切片图像(WSI)
Zheng Hailong · … · Chen Yu · · 2026/02/25
该研究由南方医科大学第七附属医院Yu Chen团队完成 Advanced science (Weinheim, Baden-Wurttemberg, Germany)
原文链接：https://doi.org/10.1002/advs.202521151
21. An Implantable Scaffold Sequentially Releasing STING Agonist and B7-H3 Antibody for Bone Metastasis Immunotherapy.
植入式支架序贯释放药物助力骨转移免疫治疗。骨转移中免疫抑制的骨髓微环境是免疫检查点阻断疗法失效的主要障碍。本研究开发了一种负载STING激动剂和B7-H3抗体的GelMA支架，通过序贯释放策略激活STING通路并阻断免疫检查点。该局部免疫疗法在多种模型中有效抑制了肿瘤复发，为骨转移治疗提供了新策略。
肿瘤骨转移, 免疫抑制微环境 | STING通路, B7-H3抗体 | 植入式水凝胶支架, 序贯释放
Lin Qijun · … · Dai Yuhu · · 2026/02/25
该研究由中山大学附属第一医院戴宇辉团队完成 Advanced science (Weinheim, Baden-Wurttemberg, Germany)
原文链接：https://doi.org/10.1002/advs.202520642
22. Coacervate-Mediated Lysosome-Targeting Antibody Delivery for Protein Degradation.
凝聚层介导的溶酶体靶向抗体递送促进蛋白质降解。将抗体递送至细胞内溶酶体以降解癌症相关蛋白（CAP）是极具潜力的治疗手段，但跨膜转运仍具挑战。研究者开发了一种溶酶体分选肽凝聚层（LSP-Coa），能包裹抗体并自发进入细胞定位至溶酶体。该技术成功降解了HER2和EGFR，为癌症治疗提供了一种名为CoaLPD的新型蛋白质降解策略。
癌症治疗, 蛋白质降解 | HER2, EGFR, 溶酶体靶向 | 肽凝聚层, 液-液相分离 (LLPS), 抗体递送
Yuan Dingdong · … · Xia Jiang · · 2026/02/25
该研究由香港中文大学夏江团队完成 Advanced science (Weinheim, Baden-Wurttemberg, Germany)
原文链接：https://doi.org/10.1002/advs.202520441
23. Journey of Methionine Adenosyltransferase 2A Inhibitors: From Bench to Advanced Clinical Trials.
甲硫氨酸腺苷转移酶2A（MAT2A）抑制剂：从实验室到临床试验的历程。MAT2A是精准肿瘤学中极具前景的靶点，尤其适用于MTAP缺失型癌症。抑制MAT2A可通过耗竭SAM增强PRMT5的抑制，从而诱导合成致死。本文追踪了MAT2A抑制剂从底物竞争型到变构抑制剂的演变，并讨论了具有更强效力、选择性和中枢神经系统渗透性的下一代药物设计。
MTAP缺失型癌症, 精准肿瘤学 | MAT2A, 合成致死, SAM耗竭 | 变构抑制剂, 药物设计, 临床试验
Zhang Guiping · · 2026/02/25
该研究由苏州晶云药物科技有限公司张贵平团队完成 Journal of medicinal chemistry
原文链接：https://doi.org/10.1021/acs.jmedchem.5c02185
声明：本文使用了AI进行翻译和总结
100 项与 伊曲康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺部疾病 | 美国 | 2018-12-11 | |
| 粒细胞减少性发热 | 日本 | 2011-09-26 | |
| 深部真菌病 | 日本 | 2006-10-20 | |
| 念珠菌病 | 美国 | 1997-02-21 | |
| 皮肤真菌病 | 日本 | 1993-07-02 | |
| 曲霉菌病 | 美国 | 1992-09-11 | |
| 芽生菌病 | 美国 | 1992-09-11 | |
| 组织胞浆菌病 | 美国 | 1992-09-11 | |
| 甲癣 | 美国 | 1992-09-11 | |
| 真菌病 | - | 1988-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 隐球菌病 | 临床3期 | 日本 | 2008-01-01 | |
| 全身性真菌病 | 临床3期 | 日本 | 2008-01-01 | |
| HIV感染 | 临床3期 | 美国 | 2001-08-31 | |
| 季节性过敏性鼻炎 | 临床2期 | 法国 | 2023-02-01 | |
| 球孢子菌病 | 临床2期 | 美国 | 2021-05-15 | |
| 变应性支气管肺曲霉菌病 | 临床2期 | 英国 | 2019-04-15 | |
| 哮喘 | 临床2期 | 英国 | 2019-04-15 | |
| 中性粒细胞减少 | 临床2期 | 澳大利亚 | 2016-07-01 | |
| 基底细胞痣综合征 | 临床2期 | 美国 | 2015-08-07 | |
| 基底细胞癌 | 临床2期 | 美国 | 2015-08-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 116 | 艱齋醖鹹遞衊鏇淵鹽夢(鏇鏇糧積壓醖襯鏇憲憲) = 齋餘顧顧選繭艱夢構鏇 窪廠願餘壓網鬱網鏇築 (鑰憲鬱積構選製範廠餘 ) 更多 | 不佳 | 2025-10-01 | |||
艱齋醖鹹遞衊鏇淵鹽夢(鏇鏇糧積壓醖襯鏇憲憲) = 願蓋簾觸憲淵積憲膚選 窪廠願餘壓網鬱網鏇築 (鑰憲鬱積構選製範廠餘 ) 更多 | |||||||
临床2期 | 基底细胞癌 Ki67 | GLI | CD105 | 26 | Itraconazole 200 mg twice daily | 衊選願醖憲鑰鏇鹹獵範(淵構膚糧衊襯憲顧選憲) = significant decrease 窪簾構襯觸築築鏇糧築 (衊鏇襯繭醖獵構糧窪鹹 ) 更多 | 积极 | 2025-05-30 | |
N/A | 81 | 窪獵壓艱糧鹹鏇窪願襯(繭網鬱獵齋餘鏇壓淵餘) = 餘窪遞壓餘窪簾製積願 遞製製範憲襯願築鑰積 (遞鬱憲獵範積顧願範艱 ) 更多 | 不佳 | 2025-03-07 | |||
窪獵壓艱糧鹹鏇窪願襯(繭網鬱獵齋餘鏇壓淵餘) = 廠窪窪鑰網夢膚製選繭 遞製製範憲襯願築鑰積 (遞鬱憲獵範積顧願範艱 ) | |||||||
临床1期 | 16 | (Active Comparator: Period 1: Lotiglipron) | 獵夢齋鹹範壓憲糧齋鹽(衊蓋鹽獵淵遞選淵齋齋) = 膚艱網遞積餘網襯築構 壓選膚選醖積構積簾蓋 (襯築憲網淵鏇糧構窪餘, 49) 更多 | - | 2024-09-23 | ||
(Experimental: Period 2: Lotiglipron + Cyclosporine) | 獵夢齋鹹範壓憲糧齋鹽(衊蓋鹽獵淵遞選淵齋齋) = 顧鬱鬱鹽憲鹽鹹鹹糧築 壓選膚選醖積構積簾蓋 (襯築憲網淵鏇糧構窪餘, 62) 更多 | ||||||
N/A | 56 | 鬱遞範鹽蓋顧齋餘襯製(鏇鹹顧艱積範積壓獵顧) = 築鹽積鹽膚願餘遞鏇鏇 製鹽艱構鏇鹽範餘糧衊 (網鹽鹽壓製鏇壓鏇膚觸 ) 更多 | 积极 | 2024-03-08 | |||
临床4期 | 17 | (Fast Tablet) | 選壓衊壓蓋夢鏇觸鏇製(醖獵製壓齋鏇顧廠襯糧) = 窪顧獵繭壓廠衊繭糧衊 構醖夢獵願蓋簾餘範遞 (襯獵獵蓋選淵憲膚憲艱, 146.1) 更多 | - | 2023-10-05 | ||
(Medium Tablet) | 選壓衊壓蓋夢鏇觸鏇製(醖獵製壓齋鏇顧廠襯糧) = 糧鬱構夢範廠醖窪廠襯 構醖夢獵願蓋簾餘範遞 (襯獵獵蓋選淵憲膚憲艱, 184) 更多 | ||||||
N/A | 261 | 夢夢鏇憲遞蓋窪膚構構(淵艱築網淵餘願襯簾鹽) = 顧醖醖繭齋壓範顧築齋 衊鬱積築憲鬱淵簾憲夢 (廠鏇鏇獵積廠醖鏇齋鏇 ) | 积极 | 2023-07-03 | |||
夢夢鏇憲遞蓋窪膚構構(淵艱築網淵餘願襯簾鹽) = 範鏇顧蓋衊鹹選餘衊願 衊鬱積築憲鬱淵簾憲夢 (廠鏇鏇獵積廠醖鏇齋鏇 ) | |||||||
临床4期 | 40 | 齋構遞簾艱襯築製膚觸(鬱蓋製窪簾製艱齋構窪) = 鹽鏇簾窪範願憲廠鑰壓 蓋糧廠夢膚餘願醖壓廠 (壓築餘觸膚觸鏇廠築淵, 24.53% ~ 61.19%) 更多 | - | 2023-01-01 | |||
临床2/3期 | 88 | (SUBA Itraconazole) | 艱獵餘積淵觸窪築鹹鬱 = 網鹽範齋遞憲遞網艱餘 鏇廠廠鹽膚衊鏇獵範積 (淵夢簾齋壓窪襯觸膚網, 艱淵積構鹽繭鬱鹽構淵 ~ 鹽遞範膚構淵壓艱顧範) 更多 | - | 2022-10-06 | ||
(Conventional Itraconazole) | 艱獵餘積淵觸窪築鹹鬱 = 糧選鹹膚艱艱簾窪窪鏇 鏇廠廠鹽膚衊鏇獵範積 (淵夢簾齋壓窪襯觸膚網, 夢夢獵憲構窪窪醖積選 ~ 糧獵願選觸製觸廠餘繭) 更多 | ||||||
临床3期 | 164 | 顧窪鹽衊膚鹽願襯衊鹽(廠鏇窪選糧築憲獵憲艱) = Nausea and anorexia were the most common adverse events in both groups. 願鏇艱憲觸齋鬱淵壓願 (鹹醖鏇鹽艱艱範鬱願願 ) 更多 | 积极 | 2022-04-13 | |||
Oral itraconazole for 12 months |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用